TheraRadar
Clinical-Stage Companies / Guangdong Raynovent Biotech

Guangdong Raynovent Biotech

Pre-Approval PRO BETA
35
Total Trials
7
Phase 3
7
Phase 2
8
Recruiting
255
Score

Pipeline by Phase

Phase 3
7
Phase 2
7
Phase 1
23

Therapeutic Focus

Obesity Influenza A Pharmacokinetics Kidney Impairment Hepatic Impairment

Clinical Trials (35)

NCT06893016 Phase 3 RECRUITING

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Started: 6/15/2025

NCT07229807 Phase 3 ACTIVE NOT RECRUITING

Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A

Started: 11/22/2025

NCT07229820 Phase 3 ACTIVE NOT RECRUITING

Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A

Started: 11/8/2025

NCT07139535 Phase 3 NOT YET RECRUITING

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Started: 8/31/2025

NCT07139548 Phase 3 NOT YET RECRUITING

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Started: 8/31/2025

NCT04683406 Phase 3 COMPLETED

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Started: 12/28/2020

NCT05620160 Phase 3 COMPLETED

Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Started: 11/12/2022

NCT06254261 Phase 2 RECRUITING

A Study of RAY1225 in Participants With Obesity

Started: 2/21/2024

NCT06656026 Phase 2 COMPLETED

Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

Started: 11/30/2024

NCT06254274 Phase 2 ACTIVE NOT RECRUITING

A Study of RAY1225 in Participants With Type 2 Diabetes

Started: 2/26/2024

NCT05692492 Phase 2 ACTIVE NOT RECRUITING

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Started: 6/3/2023

NCT04024137 Phase 2 COMPLETED

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Started: 12/7/2019

NCT06577415 Phase 1 RECRUITING

A Study of RAY1225 in Participants With Impaired Liver Function

Started: 8/26/2024

NCT07460284 Phase 1 NOT YET RECRUITING

A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants

Started: 3/15/2026

NCT05835752 Phase 1 COMPLETED

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Started: 5/18/2023

NCT07362030 Phase 1 ACTIVE NOT RECRUITING

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Started: 4/14/2025

NCT05873426 Phase 1 COMPLETED

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

Started: 3/25/2023

NCT06577428 Phase 1 COMPLETED

A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes

Started: 7/30/2024

NCT05119972 Phase 1 COMPLETED

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Started: 10/21/2021

NCT06248567 Phase 1 COMPLETED

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Started: 1/15/2024

NCT06613763 Phase 1 COMPLETED

A Study of RAY1225 in Participants With Impaired Kidney Function

Started: 9/11/2024

NCT06169085 Phase 1 COMPLETED

Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants

Started: 8/24/2023

NCT06031454 Phase 1 COMPLETED

Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

Started: 9/1/2023

NCT06362460 Phase 1 COMPLETED

Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China

Started: 9/18/2023

NCT06160622 Phase 1 COMPLETED

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

Started: 9/26/2023

NCT06164431 Phase 1 COMPLETED

Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273

Started: 11/23/2023

NCT05954624 Phase 1 COMPLETED

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Started: 7/10/2023

NCT06161259 Phase 1 COMPLETED

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

Started: 9/14/2023

NCT05942365 Phase 1 COMPLETED

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

Started: 6/25/2023

NCT06157450 Phase 1 COMPLETED

Pharmacokinetics of ZSP1273 in Elder Participants

Started: 10/11/2023

NCT05856513 Phase 1 COMPLETED

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

Started: 6/15/2023

NCT05829551 Phase 1 COMPLETED

The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants

Started: 5/20/2022

NCT05108051 Phase 1 COMPLETED

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

Started: 11/19/2020

NCT04140123 Phase 1 COMPLETED

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Started: 6/23/2020

NCT04137055 Phase 1 COMPLETED

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Started: 11/19/2019

Drug Candidates

14C-RAY1225 RAY1225 ZSP1273 ZSP1273 granules [14C] ZSP1273 ZSP1601 ZSP1603 Leritrelvir [14C] RAY1216 ZSP1273 tablet
Activity Status: Active
Last Trial Started: 3/15/2026
Last Trial Ended: 7/31/2025
Trials (12 months): 5
Completed Trials: 24
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.